Interferon antibodies in patients with infectious diseases

Biotherapy

Volumn 10, Issue 1, 1997, Pages 7-14

  Antonelli, G ^a,b   Simeoni, E ^a   Currenti, M ^a   De Pisa, F ^b   Colizzi, V ^c   Pistello, M ^a   Dianzani, F ^a  

^a UNIVERSITY OF PISA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Alpha, resistance to interferon; Antibodies to interferons; Hepatitis b; Hepatitis c; Interferons, interferon

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON ANTIBODY; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ANTIBODY PRODUCTION; ARTICLE; DRUG EFFICACY; DRUG RESPONSE; HEPATITIS; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL; SEROCONVERSION; VIRUS INFECTION;

ANTIBODIES; HUMANS; INTERFERONS; VIRUS DISEASES;

EID: 0030757162     PISSN: 0921299X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02678212     Document Type: Article

References (50)

1. Dianzani F. How to use an endogenous system as a therapeutic agent. J Interferon Res 1992; Special issue: 109-18
2. Vollbracht A, Treuner T, Flehming B, Joester KE, Niethammer D. Interferon neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 1981; 287: 496-8.
3. Antonelli G. Development of neutralizing and binding antibodies to interferon (IFN) in patients undergoing IFN therapy. Antiv Res 1994;24:235-44.
4. Trown PW, Kramer MJ, Dennin RA Jr, Connel EV, Palleroni AV, Quesada J, Gutterman JU. Antibodies to human leucocyte interferons in cancer patients. Lancet 1983; 81-4.
5. Panem S. Antibodies to interferon in man. Interferons and the immune system 1984; p. 175-183, Elsevier Amsterdam
6. De Maeyer-Guignard J, De Maeyer E. Natural antibodies to Interferon-alpha and Interferon-beta are a common feature of inbread mouse strains. J Immunol 1986; 136: 1708-11.
7. Caruso A, Bonfanti C, Colombrita D, et al. Natural antibodies to IFN-gamma in man and their increase during viral infection. J Immunol 1990; 144: 685-90.
8. Ikeda Y, et al. Naturally occurring anti-interferon alpha 2a antibodies in patients with acute viral hepatitis. Clin. Exp. Immunol. 1991; 85: 804.
9. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J. Clin. Invest. 1995; 95: 1974-8.
10. Avrameas S. Natural autoantibodies: from "horror autotoxicus" to "gnothi seauton". Immunol Today 1991; 12: 154-9.
11. Bendtzen K, Svenson M, Jonsson V, Hippe E. Autoantibodies to cytokines friends or foes? Immunol Today 1990; 11: 167-9.
12. Brook MG, McDonald JA, Karayannis P et al. Randomised controlled trial of interferon alpha 2a(rbe) (Roferon-A) for the treatment of chronic hepatitis B virus (HBV) infection: factors that influence response. Gut 1989; 30: 1116-22.
13. Porres JC, Carreno V, Ruiz M, Marron JA, Bartolom J. Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. Hepatol. 1989; 8: 351γ.
14. Lok ASF, Lai CL, Leung KY. Interferon antibodies may negate the antiviral effects of recombinant alpha-interferon treatment in patients with chronic hepatitis B virus infection. Hepatol. 1990; 12: 1266γ0.
15. Craxi A, Di Marco V, Volpes R, Palazzo U. Anti-alpha interferon antibodies after alpha interferon treatment in patients with chronic viral hepatitis. Hepato-Gastroenterol 1988; 35: 304-5.
16. !6. Perillo RP, Schiff ER, Davis GL, et al. A randomized controlled trial of interferon alpha 2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Eng J Med 1990; 323: 295-301.
17. Thurmond LM, Reese MJ. Immunochemical characterization of human antibodies to lymphoblastoid interferon. Clin Exp Immunol 1991; 86: 514-9.
18. Teitelbaum AP, Langton BC, Hung J et al. Antibody measurements in patients treated with recombinant interferon-beta. Proc AACR 1987; 28: 406.
19. Liao MJ, Axelrod HR, Kuchler M, Yip YK, Kirkbright E, Testa D. Absence of neutralizing antibodies to interferon in condyloma acuminata and cancer patients treated with natural human leukocyte interferon. J. Infect. Dis. 1992; 165: 757-60.
20. Bonetti P, Diodati G, Drago C et al. Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2a. Hepatol. 1994; 20: 416-20.
21. Roffi L, Colloredo-Mels G, Antonelli G, et al. Breakthrough during recombinant alpha-interferon therapy in patients with chronic hepatitis C virus infection: prevalence, etiology, and management. Hepatol 1995; 21: 645-9. roffi
22. Antonelli G, Current! M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991 ; 163: 882-5.
23. Antonelli G, Currenti M, Turriziani O, RivaE, Dianzani F. Relative frequency of non-neutralizing antibodies to interferon in hepatitis patients treated with different IFN alpha preparations. J Infect Dis 1992; 165: 593.
24. Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberber C, Longo DL. Resistance to recombinant interferon alpha- -2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N. Eng. J. Med. 1988; 318: 1409-13.
25. Figlin RA, Itri LM. Anti-Interferon antibodies: A perspective. Semin Hematol 1988; 25: 9-15.
26. von Wussow P, Jalschies D, Freund M, and Deicher H. Humoral response to recombinant interferon alpha 2b: results of comparative assay and clinical perspectives J. Interferon Res. 1989; 9: S25-31.
27. Larocca AP, Steven CL, Stephen CM, Colby CB, Borden EC. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta. J. Interferon Res. 1989; 9: S51-60.
28. Lok ASF; Lai CL, Wu PC, LeungEKY. Long -term follow up in a randomized controlled trial of recombinant alpha-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; ii: 298-302.
29. Jacobs S, Friedman RM, Nagabhushan TL, Oden E, Salfi M, Bordens R, Spiegel R. Detection of serum neutralizing antibodies to interferon alfa-2b (Intron A) by means of an enzyme immunoassay. J Interferon Res 1989; 9: S292.
30. Finter NB,. Why are there so many subtypes of alphainterferons? J. Interferon Res. (Spéciale issue) 1991; 185-94.
31. Palleroni A, Aglione A, Labow M et al. Preclinical evaluation of interferon immunogenicity. J Interferon Res 1994; 14(1): S128.
32. Scott Crowe J, Gewert DR, Barber KA, et al. Interferon (IFN)-alpha 2 genotype analysis of Chinese chronic hepatitis B patients undergoing recombinant IFN.alpha2a therapy. J Infect Dis 1994; 169:875-8.
33. Antonelli et al. (Manuscript in preparation)
34. Fierlbeck G, Schreiner T, Schabern B et al. Neutralizing interferon beta antibodies in melanoma patients treated with recombinant natural interferon beta. Cancer Immunol Immunoth. 1994;39:263-8.
35. Dummer R, Muller W, Nestle F, et al. Formation of neutralizing antibodies against natural Interferon-beta, but not against recombinant Interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer 1991; 67: 2300-4.
36. The IFN Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-rimitting multiple sclerosis. Neurol. 1993; 43: 655-61.
37. Jaffe HS, Chen AB, Kramer S, Sherwin SA. The absence of interferon antibody formation in patients receiving human interferon- gamma. J. Interferon Res. 1987; 6: 576-80.
38. Giannelli G, Antonelli G, Fera G, Del Vecchio S, Riva E, Broccia C, Schiraldi O, Dianzani F.Biological and clinical significance of neutralizing and binding antibodies to interferonalpha (IFN-alpha) during therapy for chronic hepatitis C. Clin. Exp. Immunol. 1994; 97: 4-9.
39. Antonelli G, Giannelli G, Current! M et al. Fate of antibody to interferon (IFN) in chronic hepatitis C patients treated with recombinant IFN alpha 2 and retreated with lymphoblastoid IFN alpha. Intern Hepatol Commun 1995; 4: 232γ.
40. Ronnblom LE, Janson ET, Perers A, Oberg KE, Alm GV. Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. Clin. Exp. Immunol. 1992; 89: 330-5.
41. Brand CM, Leadbeater L, Bellati G, Marotta F, Ideo G. Antibodies developing against a single recombinant interferon protein may neutralize other interferon-alpha subtypes. J Interferon Res 1993; 13: 121-5.
42. Nolle KU, et al. Human therapy-unduced anti-IFN alpha antibodies neutralize rlFN-alpha2 by binding to its N-terminal functional domain. J. Interferon Res. 1994; 14: SI 18.
43. Quesada J, Rios A, Swanson D, Gutterman JU. Antitumor activity of recombinant derived interferon alpha in metastatic renal cell carcinoma. J. Clin. Oncol. 1985; 3: 1522-29.
44. Milella M, Antonelli G, Santantonio T, Currenti M, Monno L, Mariano N, Angarano G, Dianzani F, Pastore G. Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection. Liver 1993; 13: 146-60.
45. Antonelli G, Giannelli G, Currenti M, et al. Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant iFN alpha 2 therapy. Clin Exp Immunol 1996; 104: 384-87.
46. Milella M, Antonelli G, Santantonio T, et al. Treatment with natural IFN of heaptitis C patients with or without antibodies to recombinant IFN. J Hepato-Gastroenterol 1995; 42: 201-4.
47. Colloredo-Mels G, Roffi L, Antonelli G, et al. Lymphoblastoid interferon in patients with chronic nAnB hepatitis showing relapse during recombinant alpha interferon therapy. Hepatitis Delta Virus, Wiley-Liss, Inc 1993; 359-64.
48. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus Ib infection. N Engl J Med 1996; 334: 77-81.
49. Nakajima S, Kuroki T, Shintani M, et al. Changes in Interferon receptors on peripheral blood mononuclear cells from patients with chronic hepatitis B being treated with interferon. Hepatol 1990; 12: 1261-65.
50. Rosenblum MG, Unger BW, Gutermab JU, Hersh EM, David GS, Frincke JM. Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Res. 1985; 45: 2421-5.